April 18, 2023 Awakn Life Sciences Signs Collaboration Agreement With University of Exeter for Upcoming Phase III Trial Phase III Trial will Assess Ketamine-Assisted Therapy for The Treatment of Severe Alcohol Use Disorder TORONTO, CANADA, 18 April, 2023 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing therapeutics to treat addiction
Cannabis Law Report
You must log in to post a comment.